From major journals, first or last author from the Institute for Cancer Research
Hermansen JU, Yin Y, Tjønnfjord GE, Mato AR, Skånland SS(2026) Evolution of the drug sensitivity landscape of chronic lymphocytic leukaemia Br J Haematol(in press) DOI 10.1111/bjh.70603, PubMed 42267774
Hektoen HH, Tsuruda KM, Mæhlen MT, Helland Å, Andreassen BK(2026) Real-world outcomes of immunotherapy in advanced NSCLC patients with comorbidities Br J Cancer(in press) DOI 10.1038/s41416-026-03491-1, PubMed 42259946
Kostas M, Munthe E, Haugsten EM, Mateus D, Sørensen V, Laerdahl JK, Szybowska P, Wiedlocha A, Lecaudey LA, Nakken S, Schink KO, Stenmark H, Wesche J(2026) Unconventional activation of the proto-oncogene FGFR1 by extracellular phosphate via H2O2-mediated kinase oxidation Cell Rep, 45(6), 117504(in press) DOI 10.1016/j.celrep.2026.117504, PubMed 42247296
Hermansen JU, Yin Y, Tjønnfjord GE, Mato AR, Skånland SS(2026) Evolution of the drug sensitivity landscape of chronic lymphocytic leukaemia Br J Haematol(in press) DOI 10.1111/bjh.70603, PubMed 42267774
Hogstrom L, Laurinavicius A, Alvarez MG, Nakken S, Guldvik IJ, Sanchez CM, Papadodima O, Voutetakis K, Mæhle PM, Zerbe N, Šekerija M, Fullaondo A, Hovig E(2026) European cancer data sharing: Analyses of an international survey Int J Med Inform, 218, 106544(in press) DOI 10.1016/j.ijmedinf.2026.106544, PubMed 42284829
Tengesdal S, Molberg Ø, Holme Ø, Ghiasvand R, Gran JT, Myklebust G(2026) Lifetime risk of malignancy in polymyalgia rheumatica: a population-based matched cohort study from southern Norway Rheumatology (Oxford)(in press) DOI 10.1093/rheumatology/keag297, PubMed 42266054
